Dupixent (dupilumab) — Medica
Chronic Obstructive Pulmonary Disease (COPD)
Initial criteria
- age ≥ 18 years
- Blood eosinophil level ≥ 300 cells/μL within previous 6 weeks OR ≥ 300 cells/μL prior to treatment with Dupixent or another monoclonal antibody that alters eosinophil levels
- Received ≥ 3 consecutive months of combination therapy with inhaled LABA, LAMA, and corticosteroid
Approval duration
initial 6 months